Dynamic Whole-body PET/CT Imaging in Clinical Oncology

Cancer Clinical Trial

— Dynamic PET/CT  

Official title:

Dynamic Whole-body PET/CT Imaging in Clinical Oncology

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06424873
• Other study ID #: 2023-02102
• Status: Recruiting
• Phase: N/A
• Start date: April 1, 2024
• Est. completion date: December 31, 2025

Study information

• Verified date: May 2024
• Source: University Hospital, Geneva
• Contact: Valentina Garibotto, Pr
• Phone: +41223727252
• Email: valentina.garibotto[@]hcuge.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to to achieve robust quantitative whole- body parametric imaging in clinically feasible scan times in patient with oncologic pathology . The main question[s] it aims to answer are: - [question 1] - [question 2] Participants will [describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items].

Description:

Whole body hybrid PET/CT imaging, making use of the standardized uptake value (SUV), is well established in clinical setting for diagnosis and staging, treatment response monitoring and radiation therapy treatment planning of a wide range of oncologic malignancies. However, the SUV metric derived from static PET data does not capture the dynamics of the PET probe biodistribution in the body. The present work proposes to fill in this notable gap: namely to merge whole-body and dynamic PET/CT imaging, to achieve robust quantitative whole- body parametric imaging in clinically feasible scan times. Our proposed approach has the potential to significantly enhance diagnostic, prognostic and treatment response monitoring capabilities of PET/CT and to fundamentally alter routine clinical practice.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients clinically indicated for whole-body PET evaluation.

2. Patient must agree to lie still in the camera.

3. Patient must be able to comply with study procedures.

4. Patient must be able to provide informed consent.

Exclusion Criteria:

1. Patients < 18 years of age.

2. Pregnant women are excluded.

Related Conditions & MeSH terms

• Cancer

Intervention

Radiation:
• PET/CT with FDG or FES
The study consists of an additional 50 minutes of imaging during the radiotracer's uptake phase prior to their clinical scan (standard of care).

Locations

Country	Name	City	State
Switzerland	Geneva University Hospitals	Geneva

Sponsors (1)

Lead Sponsor	Collaborator
Valentina Garibotto

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Standard SUV measurement metric	The standard SUV measurement metric will be compared with the measured influx rate Ki as obtained from dynamic PET/CT imaging for FDG-avid processes. We expect a correlation coefficient of at least 0.8.	through study completion , an average of 2 years
Secondary	Image quality	This will be assessed by clinical PET/CT readers, on a 5 point scale.	through study completion , an average of 2 years
Secondary	Certainty in diagnosis of FDG-avid processes	This will be assessed by clinical PET/CT readers, on a 5 point scale.	through study completion , an average of 2 years